European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...

GSK’sGSK1.44%increase; green up pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...

Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 months for Jemperli plus chemotherapy vs. 28.2 months for chemotherapy alone · Jemperli plus chemotherapy ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of adult patients with primary advanced or recurrent ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...